公开(公告)号：US20200069646A1

公开(公告)日：2020-03-05

申请号：US16555634

申请日：2019-08-29

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron Balog ,  Steven P. Seitz ,  Susheel Jethanand Nara ,  Saumya Roy ,  Srinivasan Thangathirupathy ,  Soodamani Thangavel ,  Ramesh Kumar Sistla

IPC: A61K31/415 ,  C07C275/42 ,  C07D231/12 ,  C07D401/12 ,  C07D403/12 ,  C07D261/08 ,  C07D277/22 ,  C07D285/08 ,  C07D211/60 ,  C07D317/50 ,  C07D307/36 ,  C07D333/54 ,  C07D231/56 ,  C07D221/22 ,  C07D471/04 ,  C07D487/04 ,  A61K31/17 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/42 ,  A61K31/426 ,  A61K31/433 ,  A61K31/357 ,  A61K31/341 ,  A61K31/381 ,  A61K31/5377

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.

公开(公告)号：US10544120B2

公开(公告)日：2020-01-28

申请号：US15763280

申请日：2016-09-29

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Joanne J. Bronson ,  Ling Chen ,  Jonathan L. Ditta ,  Carolyn Diane Dzierba ,  Prasada Rao Jalagam ,  Guanglin Luo ,  John E. Macor ,  Tarun Kumar Maishal ,  Susheel Jethanand Nara ,  Ramkumar Rajamani ,  Ramesh Kumar Sistla ,  Soodamani Thangavel

IPC: C07D401/04 ,  C07D413/14 ,  A61P25/16 ,  A61P25/28 ,  A61P25/18 ,  A61P25/02

Abstract: The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.

公开(公告)号：US20190262311A1

公开(公告)日：2019-08-29

申请号：US16330964

申请日：2017-09-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  Tasir Shamsul Haque ,  Louis J. Lombardo ,  John E. Macor ,  Christopher P. Mussari ,  Laxman Pasunoori ,  Michael A. Poss ,  Sreekantha Ratna Kumar ,  Shoshana L. Posy ,  David R. Tortolani ,  Brian K. Whiteley ,  Ramesh Kumar Sistla ,  Subramanya Hegde ,  Anupama Kandhi Ramachandra Reddy

IPC: A61K31/404 ,  A61P37/06 ,  A61P29/00 ,  A61K9/00

Abstract: Disclosed are compounds of Formula (I) N-oxide, or salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US10227340B2

公开(公告)日：2019-03-12

申请号：US15818826

申请日：2017-11-21

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Venkatram Reddy Paidi ,  Sreekantha Ratna Kumar ,  Abhisek Banerjee ,  Ramesh Kumar Sistla ,  Satheesh Kesavan Nair ,  William J. Pitts ,  John Hynes

IPC: C07D417/14 ,  C07D413/14 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04

Abstract: Compounds having the following formula: or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C—R7, are useful as kinase modulators, including IRAK-4 modulation.

公开(公告)号：US09790169B2

公开(公告)日：2017-10-17

申请号：US15088211

申请日：2016-04-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron Balog ,  Emily Charlotte Cherney ,  Weiwei Guo ,  Audris Huang ,  Jay A. Markwalder ,  Steven P. Seitz ,  Weifang Shan ,  David K. Williams ,  Natesan Murugesan ,  Susheel Jethanand Nara ,  Saumya Roy ,  Soodamani Thangavel ,  Ramesh Kumar Sistla ,  Srinivas Cheruku ,  Srinivasan Thangathirupathy ,  Yadagiri Kanyaboina ,  Nagalakshmi Pulicharla

IPC: C07C229/42 ,  A61K31/17 ,  A61K31/196 ,  A61K31/277 ,  A61K31/351 ,  A61K31/382 ,  A61K31/397 ,  A61K31/428 ,  A61K31/437 ,  A61K31/445 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/538 ,  A61K39/395 ,  C07C255/58 ,  C07C275/40 ,  C07D205/04 ,  C07D211/14 ,  C07D239/47 ,  C07D265/36 ,  C07D277/64 ,  C07D295/155 ,  C07D309/04 ,  C07D335/02 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D309/14 ,  C07D407/12 ,  C07D487/08 ,  C07D265/30 ,  C07D207/08 ,  C07D211/08 ,  C07D307/22 ,  C07C255/57 ,  C07C235/38 ,  C07C235/56

CPC classification number: C07C275/40 ,  A61K31/17 ,  A61K31/196 ,  A61K31/277 ,  A61K31/351 ,  A61K31/382 ,  A61K31/397 ,  A61K31/428 ,  A61K31/437 ,  A61K31/445 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/538 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  C07C229/42 ,  C07C233/81 ,  C07C235/38 ,  C07C235/56 ,  C07C255/57 ,  C07C255/58 ,  C07C275/30 ,  C07C275/42 ,  C07D205/04 ,  C07D207/08 ,  C07D207/12 ,  C07D211/08 ,  C07D211/14 ,  C07D239/34 ,  C07D239/47 ,  C07D265/30 ,  C07D265/36 ,  C07D277/64 ,  C07D295/155 ,  C07D307/22 ,  C07D309/04 ,  C07D309/14 ,  C07D317/46 ,  C07D335/02 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

公开(公告)号：US20170231999A1

公开(公告)日：2017-08-17

申请号：US15584818

申请日：2017-05-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron Balog ,  Emily Charlotte Cherney ,  Weiwei Guo ,  Audris Huang ,  Jay A. Markwalder ,  Steven P. Seitz ,  Weifang Shan ,  David K. Williams ,  Natesan Murugesan ,  Susheel Jethanand Nara ,  Saumya Roy ,  Soodamani Thangavel ,  Ramesh Kumar Sistla ,  Srinivas Cheruku ,  Srinivasan Thangathirupathy ,  Yadagiri Kanyaboina ,  Nagalakshmi Pulicharla

IPC: A61K31/538 ,  A61K31/17 ,  A61K31/196 ,  A61K31/277 ,  A61K31/351 ,  A61K31/382 ,  A61K31/397 ,  A61K31/428 ,  A61K31/437 ,  A61K31/445 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5375 ,  A61K31/5377 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07C275/40 ,  A61K31/17 ,  A61K31/196 ,  A61K31/277 ,  A61K31/351 ,  A61K31/382 ,  A61K31/397 ,  A61K31/428 ,  A61K31/437 ,  A61K31/445 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/538 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  C07C229/42 ,  C07C233/81 ,  C07C235/38 ,  C07C235/56 ,  C07C255/57 ,  C07C255/58 ,  C07C275/30 ,  C07C275/42 ,  C07D205/04 ,  C07D207/08 ,  C07D207/12 ,  C07D211/08 ,  C07D211/14 ,  C07D239/34 ,  C07D239/47 ,  C07D265/30 ,  C07D265/36 ,  C07D277/64 ,  C07D295/155 ,  C07D307/22 ,  C07D309/04 ,  C07D309/14 ,  C07D317/46 ,  C07D335/02 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

公开(公告)号：US11739098B2

公开(公告)日：2023-08-29

申请号：US17699944

申请日：2022-03-21

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  Christopher P. Mussari ,  Trevor C. Sherwood ,  John L. Gilmore ,  Tasir Shamsul Haque ,  Brian K. Whiteley ,  David R. Tortolani ,  Shoshana L. Posy ,  John E. Macor ,  Louis J. Lombardo ,  Ramesh Kumar Sistla ,  Anupama Kandhi Ramachandra Reddy ,  Subramanya Hegde ,  Laxman Pasunoori ,  Sreekantha Ratna Kumar

IPC: C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04

CPC classification number: C07D498/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04

Abstract: Disclosed are compounds of Formula (I)




or salts thereof, wherein Ring Het, R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US20230255941A1

公开(公告)日：2023-08-17

申请号：US18307119

申请日：2023-04-26

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. DYCKMAN ,  Dharmpal S. Dodd ,  Tasir Shamsul Haque ,  Louis J. Lombardo ,  John E. Macor ,  Christopher P. Mussari ,  Laxman Pasunoori ,  Sreekantha Ratna Kumar ,  Trevor C. Sherwood ,  Shoshana L. Posy ,  Ramesh Kumar Sistla ,  Subramanya Hegde ,  Anupama Kandhi Ramachandra Reddy

IPC: A61K31/4196 ,  C07D249/00 ,  A61K31/437 ,  A61K31/4427 ,  A61K45/06 ,  C07D471/04

CPC classification number: A61K31/4196 ,  C07D249/00 ,  A61K31/437 ,  A61K31/4427 ,  A61K45/06 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (I)




or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US20230167131A1

公开(公告)日：2023-06-01

申请号：US17799028

申请日：2021-02-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Kumaravel Selvakumar ,  Venkatram Paidi ,  Srinivasan Thangathirupathy ,  Vijaya Kumar Cm ,  Tirupathi Rao Alajangi ,  Mallikarjun Reddy Sura ,  Krishna Mahadevu ,  Ramesh Kumar Sistla ,  Piyush Agarwal ,  Arul Mozhi Subbiah Karuppiah ,  Jalathi S. Nair ,  Ooha Morampudi ,  Manoranjan Panda ,  Joseph A. Tino ,  Robert J. Cherney ,  John V. Duncia ,  Daniel S. Gardner ,  T. G. Murali Dhar ,  Audrey Graham Ross ,  Paul E. Gormisky ,  Xiao Zhu ,  Boris M. Seletsky ,  Alyssa H. Antropow ,  Deqiang Niu ,  Zhengdong Zhu ,  Guobin Miao ,  Julio Herman Cuervo

IPC: C07D519/00 ,  C07D471/04 ,  C07D487/04 ,  C07D409/14 ,  C07D405/14 ,  C07D413/14

CPC classification number: C07D519/00 ,  C07D471/04 ,  C07D487/04 ,  C07D409/14 ,  C07D405/14 ,  C07D413/14

Abstract: The disclosure generally relates to substituted heterocyclic compounds of Formula (Ia), which are inhibitors of PAD4, method for preparing these compounds, pharmaceutical compositions comprising these compounds and use of these compounds in the treatment of a disease or a disorder associated with PAD4 enzyme activity.

公开(公告)号：US20210163443A1

公开(公告)日：2021-06-03

申请号：US17108024

申请日：2020-12-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pravin Sudhakar Shirude ,  Satheesh Kesavan Nair ,  Ramesh Kumar Sistla ,  Ashit K. Ganguly ,  Ramakanth Sarabu

IPC: C07D401/06 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14

Abstract: Disclosed are compounds of Formula I, and pharmaceutically acceptable salts thereof: Also disclosed are pharmaceutical compositions thereof as well as methods for using the compounds in treating a variety of diseases such as, for example, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, ischemic damage, inflammatory diseases, cancers, musculoskeletal diseases, cardiovascular diseases, transplant rejection, multiple sclerosis, systemic sclerosis and neurodegenerative diseases.